BMT characteristics
| . | Characteristic . |
|---|---|
| Donor | HLA identical brother |
| ABO match | Donor B pos, Rec 0 pos |
| Conditioning regimen | Cy 20 mg/kg recipient body weight + TAI 500 cGy |
| Cell infused | 19.8 × 108/kg |
| GVHD prophylaxis | CyA 3 mg/kg. Then reduced to maintain serum through levels between 50-100 ng/mL for 15 months |
| Engraftment | PMN (> 0.5 × 109/L) day + 8, Plt (> 50 × 109/L for 3 consecutive days) day + 35 |
| Toxicity | Grade I mucositis |
| GVHD | No |
| . | Characteristic . |
|---|---|
| Donor | HLA identical brother |
| ABO match | Donor B pos, Rec 0 pos |
| Conditioning regimen | Cy 20 mg/kg recipient body weight + TAI 500 cGy |
| Cell infused | 19.8 × 108/kg |
| GVHD prophylaxis | CyA 3 mg/kg. Then reduced to maintain serum through levels between 50-100 ng/mL for 15 months |
| Engraftment | PMN (> 0.5 × 109/L) day + 8, Plt (> 50 × 109/L for 3 consecutive days) day + 35 |
| Toxicity | Grade I mucositis |
| GVHD | No |